Britain has begun building a nationwide dementia clinical trial registration platform to speed up the development of dementia drugs. The strategy is to achieve consolidation of dementia research data scattered across the country into one, expand clinical trial participation, and use this to bolster investment in life sciences and research and development (R&D) competitiveness.
On the 12th (local time), according to the Financial Times (FT), the U.K. government, charities, and the pharmaceutical industry launched a nationwide virtual registration platform for people with dementia and those at risk, "BARBARA (Brain Ageing Registry for Biomarkers, Access to Trials, Research and Adoption)." The U.K. government, charities, and the pharmaceutical industry are jointly funding the platform.
BARBARA is a platform that links 180 existing dementia research databases and population health studies, designed to efficiently find clinical trial participants. Through this, drug corporations can quickly secure suitable clinical trial subjects, and people with dementia and those at high risk can take part in studies appropriate for them. James Bethell, chair of the BARBARA project steering committee and former U.K. Minister for Innovation at the Department of Health and Social Care, said, "BARBARA will be the world's leading dementia data registration system for corporations seeking to test treatments."
Currently, 158 Alzheimer's treatments are being developed through 192 clinical trials worldwide. Drug candidates other than Alzheimer's treatments are also in development. In the industry, difficulty in securing suitable clinical trial participants is cited as one of the biggest obstacles to developing new dementia drugs. Former Minister Bethell said only 173 patients in England took part in late-stage, commercially sponsored Alzheimer's clinical trials in 2024–2025.
In this situation, BARBARA focuses on integrating research data nationwide to pre-screen clinical trial subjects and shorten recruitment periods. The project's backers believe that linking early diagnosis technology using blood biomarkers (biological indicators that diagnose disease) with the platform will allow even high-risk patients before symptoms emerge to join trials, accelerating new drug development. They also expect it to aid the development of precision dementia treatments using genetic analysis.
In particular, the project's backers expect BARBARA to serve not only dementia drug development but also as a base for attracting clinical trials and research and development (R&D) investment by global pharmaceutical companies. They judge it could help improve the slumping life sciences investment climate after the National Institute for Health and Care Excellence (NICE) recently found that the Alzheimer's treatments "lecanemab" and "donanemab" were not sufficiently cost-effective in terms of expense.
Sally John, executive vice president for informatics and predictive sciences at Bristol Myers Squibb (BMS), said, "BARBARA will help Alzheimer's research ask better questions and bring forward studies for patients who need help," adding, "it appears we will build a unique data set that artificial intelligence (AI) and Machine Learning can analyze."
The specific size of the investment to be put into building the platform is slated to be announced within this year. Through this platform, Britain plans to both accelerate dementia drug development and develop itself into a hub for attracting global clinical trials and life sciences investment.